BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Endothelial cell
,
Hematopoietic cell
,
Tamoxifen
,
rs6983267
,
GATA1
,
Coagulation
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
RNA cap 4 binding
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
No tissues found
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
No diseases found
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
No compounds found
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
No perturbed genes found
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
GSE22903_RW_MO_Polyribosomal associated mRNA in knockdowns of small and large ribosomal proteins
Cervical cancer HeLa cells transfected with ILF3 siRNA and with or without Poly(I:C) treatment
Cervical cancer HeLa cells transfected with ILF3 siRNA and Poly(I:C) - polysomal RNA fractions
Breast adenocarcinoma MDA-LM2 cells after transfection with structural RNA stability element decoy
Cervical cancer HeLa cell RNA associated with CBP20 (NCBP2) or ARS2 (SRRT)
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for RNA cap 4 binding
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Leukocyte Morphological Parameters as Prognostic Markers in CAP
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autolog…
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Pat…
Sevelamer for Reducing Endotoxemia and Immune Activation
The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ